High-resolution mapping of mitotic DNA synthesis under conditions of replication stress in cultured cells.
Groelly FJ. et al, (2023), STAR Protoc, 4
Targeting DNA damage response pathways in cancer.
Groelly FJ. et al, (2023), Nat Rev Cancer, 23, 78 - 94
MiR-182-3p targets TRF2 and impairs tumor growth of triple-negative breast cancer.
Dinami R. et al, (2023), EMBO Mol Med, 15
Mitotic DNA synthesis is caused by transcription-replication conflicts in BRCA2-deficient cells.
Groelly FJ. et al, (2022), Mol Cell, 82, 3382 - 3397.e7
Anti-tumoural activity of the G-quadruplex ligand pyridostatin against BRCA1/2-deficient tumours.
Groelly FJ. et al, (2022), EMBO Mol Med, 14
A transcription-based mechanism for oncogenic β-catenin-induced lethality in BRCA1/2-deficient cells.
Dagg RA. et al, (2021), Nat Commun, 12
DNA Damage and Cancer Immunotherapy: A STING in the Tale.
Reisländer T. et al, (2020), Mol Cell, 80, 21 - 28
The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.
Tarsounas M. and Sung P., (2020), Nat Rev Mol Cell Biol, 21, 284 - 299
Radiolabeled Oligonucleotides Targeting the RNA Subunit of Telomerase Inhibit Telomerase and Induce DNA Damage in Telomerase-Positive Cancer Cells.
Jackson MR. et al, (2019), Cancer Res, 79, 4627 - 4637
BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors.
Reisländer T. et al, (2019), Nat Commun, 10
Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance.
Tacconi EM. et al, (2019), EMBO Mol Med, 11
Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.
Gogola E. et al, (2019), Cancer Cell, 35, 950 - 952
Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance.
Tacconi EM. et al, (2019), EMBO Mol Med
Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.
Gogola E. et al, (2018), Cancer Cell, 33, 1078 - 1093.e12
99mTc-duramycin imaging reveals variable tissue toxicity of cancer drugs
Sneddon D. et al, (2018), JOURNAL OF NUCLEAR MEDICINE, 59
BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.
Tacconi EM. et al, (2017), EMBO Mol Med, 9, 1398 - 1414
MUS81 nuclease activity is essential for replication stress tolerance and chromosome segregation in BRCA2-deficient cells.
Lai X. et al, (2017), Nat Commun, 8
Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells.
Schoonen PM. et al, (2017), Nat Commun, 8
Progression through mitosis promotes PARP inhibitor induced cytotoxicity in homologous recombination deficient cancer cells
Schoonen PM. et al, (2017), CANCER RESEARCH, 77